Silvia Svegliati

Via Tronto 10/A
Ancona, 60126, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Micro- and Macro-Vascular Disease in Systemic Sclerosis and Very Early SSc (VEDOSS): Results from a Monocentric Observational Study.

Micro- and Macro-Vascular Disease in Systemic Sclerosis and Very Early SSc (VEDOSS): Results from a Monocentric Observational Study.

Journal: Biomedicines

Published: February 02, 2026

Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine.

Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine.

Journal: International journal of molecular sciences

Published: July 13, 2023

Adeno-Associated Virus Type 5 Infection via PDGFRα Is Associated With Interstitial Lung Disease in Systemic Sclerosis and Generates Composite Peptides and Epitopes Recognized by the Agonistic Immunoglobulins Present in Patients With Systemic Sclerosis.

Adeno-Associated Virus Type 5 Infection via PDGFRα Is Associated With Interstitial Lung Disease in Systemic Sclerosis and Generates Composite Peptides and Epitopes Recognized by the Agonistic Immunoglobulins Present in Patients With Systemic Sclerosis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: February 06, 2023

PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis.

PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis.

Journal: International journal of molecular sciences

Published: February 28, 2022

Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches.

Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches.

Journal: Biomedicines

Published: November 25, 2021

Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.

Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.

Journal: Frontiers in immunology

Published: October 30, 2021

Tocilizumab in COVID-19 interstitial pneumonia.

Tocilizumab in COVID-19 interstitial pneumonia.

Journal: Journal of internal medicine

Published: September 23, 2020

Corrigendum to: Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease-associated spondyloarthritis.

Corrigendum to: Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease-associated spondyloarthritis.

Journal: Rheumatology (Oxford, England)

Published: August 09, 2020

Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease-associated spondyloarthritis.

Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease-associated spondyloarthritis.

Journal: Rheumatology (Oxford, England)

Published: January 08, 2020

NADPH oxidase, oxidative stress and fibrosis in systemic sclerosis.

NADPH oxidase, oxidative stress and fibrosis in systemic sclerosis.

Journal: Free radical biology & medicine

Published: January 12, 2018

Metabolomic profile of systemic sclerosis patients.

Metabolomic profile of systemic sclerosis patients.

Journal: Scientific reports

Published: November 29, 2017

Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease.

Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease.

Journal: The Journal of rheumatology

Published: October 31, 2017

Showing 1-12 of 23

Last Updated: 09/26/2026